From Company Creation through Public Investing
The Frazier Life Sciences team invests in and builds companies developing and commercializing novel therapeutics.
Passage Bio Announces Pricing of Initial Public Offering
Arcutis Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Frazier Healthcare Partners Closes Oversubscribed $617 Million Life Sciences Fund
Frazier Healthcare Partners Announces Multiple Promotions on its Life Sciences Team
